# Applications of Nanobiotechnology in Medicine

**Authors:** David Aebisher, Klaudia Dynarowicz, Izabela Rudy, Kacper Rogóż, Dorota Bartusik-Aebisher, Aleksandra Kawczyk-Krupka

PMC · DOI: 10.3390/life16020302 · 2026-02-10

## TL;DR

Nanobiotechnology uses tiny structures to improve medicine by enabling precise drug delivery, diagnostics, and personalized treatments.

## Contribution

The paper highlights novel applications of nanobiotechnology in theranostics and precision medicine.

## Key findings

- Nanostructures improve therapeutic and diagnostic efficacy in cancer and gene therapy.
- Nanobiotechnology supports early disease detection and personalized treatment strategies.
- Challenges include safety, biocompatibility, and translating lab results to clinical use.

## Abstract

Nanobiotechnology, defined as the application of nanotechnology in biology and medicine, refers to the use of nanometric structures to solve complex clinical problems through precise interaction at the molecular level. Nanostructures such as lipid, polymer, and metallic nanoparticles offer unique properties that enable improved therapeutic and diagnostic efficacy and the integration of diagnostic and therapeutic functions within the concept of theranostics. Major applications of nanobiotechnology include targeted drug delivery in cancer, infection, and gene therapy; advanced molecular diagnostics and biosensors; tissue engineering and regeneration; and immune system modulation through modern nanotechnology-based vaccines and immunotherapies. The clinical significance of these technologies lies in their ability to improve drug bioavailability, minimize adverse effects, increase sensitivity in early disease detection, and support personalized treatment strategies. Nanobiotechnology also contributes to the development of precision medicine by combining diagnostics and therapy within a single nanosystem. Despite promising results, significant challenges remain related to safety, biocompatibility, toxicity, and translation from laboratory studies to clinical applications. Further research is needed to standardize methods, assess the long-term health impact of nanomaterials, and develop regulatory frameworks to fully realize the potential of nanobiotechnology in medicine.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** mitochondrial dysfunction (MESH:D028361), Parkinson's disease (MESH:D010300), chronic inflammation (MESH:D007249), injury to (MESH:D014947), neurodegenerative (MESH:D019636), congenital defects (MESH:D000013), fibrosis (MESH:D005355), Alzheimer's (MESH:D000544), Tumor (MESH:D009369), Neurological Diseases (MESH:D020271), autoimmune diseases (MESH:D001327), burns (MESH:D002056), metabolic disorders (MESH:D008659), neurological disorders (MESH:D009461), Toxicity (MESH:D064420), bone defects (MESH:D001847), ulcers (MESH:D014456), infection (MESH:D007239), hypersensitivity (MESH:D004342), granuloma (MESH:D006099), inflammatory drugs (MESH:D000081015), Infectious and Inflammatory Diseases (MESH:D003141), brain tumors (MESH:D001932)
- **Chemicals:** metal (MESH:D008670), Gold (MESH:D006046), polymer (MESH:D011108), Carbon (MESH:D002244), graphene oxide (MESH:C000628730), polysaccharides (MESH:D011134), PEG (MESH:D011092), iron (MESH:D007501), water (MESH:D014867), Doxil (MESH:C506643), silver (MESH:D012834), Iron oxide (MESH:C000499), doxorubicin (MESH:D004317), Inorganic (-), Graphene (MESH:D006108), Hydroxyapatite (MESH:D017886), amphotericin B (MESH:D000666), asbestos (MESH:D001194), carbon nanotubes (MESH:D037742), Lipid (MESH:D008055), heavy metal (MESH:D019216), folic acid (MESH:D005492), ROS (MESH:D017382), lanthanoid (MESH:D028581), AmBisome (MESH:C068538)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941592/full.md

---
Source: https://tomesphere.com/paper/PMC12941592